Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A topical combination drug that contains **triamcinolone acetonide** (a synthetic corticosteroid with anti-inflammatory and antipruritic effects), **nystatin** (an antifungal polyene that binds to ergosterol in fungal cell membranes, causing increased permeability and cell death), and **gramicidin** (a peptide antibiotic active against gram-positive bacteria by increasing membrane permeability). This combination is used primarily for corticosteroid-responsive skin conditions complicated by secondary bacterial and fungal infections. It acts by reducing inflammation and suppressing immune responses (triamcinolone acetonide), directly killing susceptible fungi (nystatin), and eliminating certain bacteria (gramicidin)[4][9][11][12][13].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triamcinolone acetonide + nystatin + gramicidin.